8-K: Silence Therapeutics Reports Q1 2025 Financial Results, Extends Cash Runway into 2028

Silence Therapeutics announced its Q1 2025 financial results, highlighting progress in clinical trials and extending its cash runway into 2028 through cost-saving initiatives.

Summary

• Silence Therapeutics reported its financial results for the first quarter ended March 31, 2025.
• The company is advancing enrollment in the SANRECO Phase 2 study of divesiran for Polycythemia Vera (PV), expecting to complete enrollment by the end of 2025.
• Additional Phase 1 results from the SANRECO study will be presented at the European Hematology Association (EHA) 2025 Annual Congress in June.
• Core Phase 3 readiness activities for zerlasiran in cardiovascular disease are on track for completion by mid-2025, with partnering discussions ongoing.
• A Phase 1 study of SLN312, licensed to AstraZeneca, is ongoing.
• Tim McInerney was appointed to the company's Board of Directors, effective May 5, 2025.
• The company's cash and cash equivalents, and short-term investments totaled $136.5 million as of March 31, 2025, compared to $147.3 million at the end of 2024.
• Research and development (R&D) expenses increased to $20.8 million, up from $11.8 million in Q1 2024, due to clinical trial advancements and increased manufacturing activities.
• General and administrative (G&A) expenses increased to $7.7 million, up from $6.7 million in Q1 2024, due to additional reporting and compliance requirements.
• Net loss was $28.5 million, or $0.20 per share, compared to a net loss of $2.3 million, or $0.02 per share, in Q1 2024.
• The company has implemented cost savings initiatives to extend its cash runway into 2028, including reductions in G&A and prioritization of early-stage research projects.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company is making progress in its clinical programs and extending its cash runway, the increased net loss and rising expenses are concerning.

Positives

• The company has a strong cash position of $136.5 million.
• The cash runway has been extended into 2028 through cost savings initiatives.
• Clinical trials for divesiran and zerlasiran are progressing as planned.
• A new board member with extensive experience has been appointed.

Negatives

• The company experienced a significant net loss of $28.5 million in Q1 2025, compared to a net loss of $2.3 million in Q1 2024.
• R&D and G&A expenses have increased compared to the same period last year.
• Cash and cash equivalents decreased from $121.330 million to $64.886 million.

Risks

• The company has a history of net operating losses.
• The company's ability to obtain necessary capital to fund its clinical programs is a risk.
• The early stages of clinical development of the company's product candidates pose risks.
• The company's reliance on third-party suppliers and manufacturers is a risk.
• The company's ability to adequately maintain intellectual property rights for its product candidates is a risk.

Future Outlook

Silence Therapeutics aims to continue advancing its clinical programs, particularly divesiran and zerlasiran, while prudently managing its finances to extend its cash runway into 2028.

Management Comments

• 'Silence delivered another strong quarter focused on clinical and operational execution,' said Craig Tooman, President and Chief Executive Officer at Silence.
• 'We remain focused on advancing enrollment into the SANRECO Phase 2 study of divesiran, a first-in-class siRNA program in PV, and continue to be on-track to complete enrollment by the end of this year,' said Craig Tooman, President and Chief Executive Officer at Silence.
• 'We ended the first quarter with over $136 million in cash, cash equivalents, and short-term investments,' said Rhonda Hellums, Chief Financial Officer at Silence.
• 'To maintain a healthy financial position while prioritizing the advancement of our core PV program, we are implementing cost savings initiatives and further extending our cash guidance into 2028,' said Rhonda Hellums, Chief Financial Officer at Silence.
• 'We remain committed to realizing the vast potential of our proprietary mRNAi GOLD platform and will continue to invest prudently in areas where we see the greatest opportunity to enhance value to Silence stakeholders,' said Rhonda Hellums, Chief Financial Officer at Silence.

Industry Context

Silence Therapeutics is operating in the competitive siRNA therapeutics market, focusing on cardiovascular, hematology, and rare diseases, similar to companies like Alnylam Pharmaceuticals and Arrowhead Pharmaceuticals, which are also developing RNAi-based therapies.

Comparison to Industry Standards

• Alnylam Pharmaceuticals, a leader in RNAi therapeutics, reported Q1 2024 revenues of $343 million, showcasing the potential revenue generation in this field.
• Arrowhead Pharmaceuticals is also advancing multiple RNAi candidates in clinical trials, focusing on liver diseases and other therapeutic areas.
• Silence Therapeutics' cash position of $136.5 million is relatively smaller compared to Alnylam's $2.3 billion in cash and investments, indicating a need for strategic partnerships or further funding to compete effectively.

Management Changes

Stakeholder Impact

• Shareholders: Cost savings initiatives and extended cash runway could be viewed positively, but increased net loss is a concern.
• Employees: Cost savings initiatives may lead to restructuring or reduced resources in some areas.
• Customers: Continued progress in clinical trials could lead to new treatment options for patients.
• Suppliers: Prioritization of key projects may impact the volume of work for some suppliers.

Next Steps

• Advance patient enrollment into the Phase 2 portion of the SANRECO study of divesiran.
• Present additional Phase 1 results from the SANRECO study at the EHA 2025 Annual Congress.
• Complete core Phase 3 readiness activities for zerlasiran.
• Continue partnering discussions for potential Phase 3 development of zerlasiran.

Key Dates

Keywords

Silence Therapeutics, financial results, divesiran, zerlasiran, clinical trials, cash runway, siRNA, mRNAi GOLD platform, SANRECO study, EHA, SLN312